Industry news

Russian scientists work to ban “ride on virus”

Marchmont Innovation News

Biochemists in Novosibirsk, in Siberia, are looking for agents that are capable of suppressing the development and propagation of orthopoxviruses, a family of pathogenic viruses potentially dangerous to human beings, portal Science in Siberia reported. 

Rare disease marketers try creative gambits to stand out online

Beth Snyder Bulik / FiercePharmaMarketing

Rare disease marketing and digital go hand-in-hand. Targeted online communications are efficient and economical for orphan drugs' small target audiences--and typically smaller marketing budgets.

Russian vaccine to prevent B-type hepatitis to hit global market

Marchmont Innovation News

A new Russian vaccine to prevent B-type hepatitis is entering the global market. According to experts, taking an injection with the new vaccine will give a person long-term confidence as it is said to stay active for many years. 

Global regenerative medicine sector on a roll, report finds

Peter Winter / BioWorld

The Alliance for Regenerative Medicine (ARM) has released its first quarter industry report that describes a regenerative medicine sector, which includes gene and cellular therapies, in healthy shape. Growth is evident on a number of fronts, even in the wake of the uncertain financial environment that has prevailed and depressed the capital market since the beginning of the year.

13 May 2016

Tobira Therapeutics Announces Publication of Phase 1 Study Results Showing Cenicriviroc Safety in Cirrhotic Patients

Tobira Therapeutics, Inc.  ( NASDAQ : TBRA), a biopharmaceutical company developing novel treatments for non-alcoholic steatohepatitis (NASH) and other serious immuno-inflammatory and fibrotic diseases, today announced that data from a study of cenicriviroc (CVC) in participants with liver cirrhosis and mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment, has been accepted as a manuscript for publication in the journal Clinical Translational Science. 

U.S. probes contracts between drugmakers, pharmacy benefit managers

Natalie Grover / Reuters

The U.S. Attorney's Office for the Southern District of New York is investigating contracts between drugmakers and companies that manage prescription benefits, according to regulatory filings.

Researchers identify genetic links to educational attainment

U.S. National Institute of Health

An international team of researchers has identified 74 areas of the human genome associated with educational attainment. It is well known that social and other environmental factors influence education, but these findings, reported by the Social Science Genetics Association Consortium (SSGAC) and supported in part by the National Institutes of Health, suggest that large genetics analyses may be able to help discover biological pathways as well.

Yale creates Hugo to make it easier for patients to open EHRs up to researchers

Nick Paul Taylor / Fierce Biotech

Yale School of Medicine has unveiled a platform designed to make it easier for patients to contribute to research. The platform, named Hugo, enables patients to access their electronic health records (EHRs) from multiple parts of the healthcare system and share the pooled resource with researchers.

FDA rolls out draft guidance for 3-D printed medical devices

Emily Wasserman / FierceMedicalDevices

The FDA has unveiled new draft guidance for 3-D printing, laying out its thoughts on the technology and device regulation as more med tech companies jump into the fast-growing field.

China gearing up for antitrust pricing drive against drugmakers

EJ Lane / FeircePharmaAsia

Foreign and domestic drug and device companies in China face the prospect of "large-scale and systematic" antitrust probes with several, including Pfizer, already asked to provide operational details, China Daily reports.